BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35950848)

  • 1. Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review.
    Xu J; Bai Y; Li E; Xu N; Shi D; Qian J
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):981-998. PubMed ID: 35950848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
    Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
    Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
    Shirakawa T; Kato K; Nagashima K; Nishikawa A; Sawada R; Takahashi N; Shoji H; Sasaki Y; Honma Y; Iwasa S; Takashima A; Okita N; Hamaguchi T; Yamada Y; Shimada Y
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1207-15. PubMed ID: 25267597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed.
    Meemanage M; Spender LC; Collinson D; Iannetta J; Challapalli P; Turbitt J; Clark C; Baxter M; Murray G; Walsh S; Miedzybrodzka Z; Petty RD
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):361-377. PubMed ID: 33169187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma.
    Li Y; Ji Y; Shen L; Yin X; Huang T; Deng B; Guo H; Wu Y; Chen Y
    Front Oncol; 2022; 12():1015302. PubMed ID: 36605427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
    Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
    Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.
    Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y
    Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study.
    Wang W; Yi Y; Jia Y; Dong X; Zhang J; Song X; Song Y
    Thorac Cancer; 2022 Mar; 13(6):824-831. PubMed ID: 35118824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature.
    Ter Veer E; Haj Mohammad N; van Valkenhoef G; Ngai LL; Mali RM; van Oijen MG; van Laarhoven HW
    Cancer Metastasis Rev; 2016 Sep; 35(3):439-56. PubMed ID: 27417221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
    Okunaka M; Kotani D; Demachi K; Fujiwara H; Sakashita S; Yoshino T; Fujita T; Kojima T
    Esophagus; 2022 Apr; 19(2):240-249. PubMed ID: 34611830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
    Dai X; Tao L; Wang J; Wu W; Bian W; Dai X; Chen S
    Cancer Med; 2023 Aug; 12(15):16108-16118. PubMed ID: 37325938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil.
    Victor CR; Fujiki FK; Takeda FR; Hoff PMG; de Castria TB
    J Glob Oncol; 2019 Jul; 5():1-10. PubMed ID: 31365299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma.
    Abraham P; Gricar J; Zhang Y; Shankaran V
    Adv Ther; 2020 Jul; 37(7):3392-3403. PubMed ID: 32533533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
    Zhu X; Shanzhou Q; Li D; Pang X; Ma D
    BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis.
    Zhang F; Wang Y; Wang ZQ; Sun P; Wang DS; Jiang YX; Zhang DS; Wang FH; Xu RH; Li YH
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27868295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
    Zhao W; Ke S; Cai X; Zuo Z; Shi W; Qiu H; Cai G; Gong Y; Wu Y; Ruan S; Chen Y
    Radiother Oncol; 2023 Jul; 184():109679. PubMed ID: 37105302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
    Guo X; Zhao F; Ma X; Shen G; Ren D; Zheng F; Du F; Wang Z; Ahmad R; Yuan X; Zhao J; Zhao J
    BMC Cancer; 2019 Nov; 19(1):1125. PubMed ID: 31747911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
    Catenacci DV; Chao J; Muro K; Al-Batran SE; Klempner SJ; Wainberg ZA; Shah MA; Rha SY; Ohtsu A; Liepa AM; Knoderer H; Chatterjee A; Van Cutsem E
    Oncologist; 2021 Oct; 26(10):e1704-e1729. PubMed ID: 34288262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.